Status: Recruiting
A Study Comparing KB803 and Matched Placebo in Patients With Dystrophic Epidermolysis Bullosa
KB803-EYE-01 is a Phase 3 double-blind, randomized, placebo-controlled, crossover study to evaluate the safety and efficacy of KB803 versus matched placebo in pediatric and adult subjects with recurrent corneal abrasions due to dystrophic epidermolysis bullosa (DEB).
Participants needed: 16
Trial details
Phase: Phase 3Age: 6+Biological sex: AllType: InterventionalSponsor: Krystal Biotech, Inc.Updated: Mar 12, 2026Locations: 5
Eligibility criteria
The subject and/or their parent/legal guardian must provide informed consent/ass... [+3]
Initiation of any new treatment regimen or change in treatment for ocular diseas... [+5]